Growth Hormone News and Research

RSS

Growth hormone (GH) is a protein-based peptide hormone. It stimulates growth, cell reproduction and regeneration in humans and other animals. Growth hormone is a 191-amino acid, single-chain polypeptide that is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland.

Steroids and weight loss products can accelerate hair loss, says hair loss expert

In a study due to be released next month, the world's leading hair transplant and hair loss expert Dr. Larry Shapiro will show that men and women have been losing their hair from using popular weight loss and work out products that contain whey protein isolate- and it's not just their genes that are to blame.

19 Feb 2010

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

ACCESS PHARMACEUTICALS, INC. announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.

5 Feb 2010

Akela announces the outcomes of two legal cases involving former employees

Akela a leader in the development of therapeutics for the treatment of pain and its wholly owned subsidiary, PharmaForm, a leader in the contract pharmaceutical development and manufacturing business, today announced the outcomes of two legal cases involving former employees.

4 Feb 2010

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

Teva Pharmaceutical Industries Ltd. announced today the availability of new resources to support the recently introduced Tjet® injector system, a needle-free device designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

3 Feb 2010

PROLOR Biotech reports the EC approval of Merck's ELONVA

PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH) today noted the European Commission (EC) approval of Merck & Co., Inc.'s ELONVA®, a long-acting CTP-modified version of the fertility drug follicle stimulating hormone (FSH).

30 Jan 2010

Adipose tissue, a promising new source of HSPCs

Bone marrow is a leading source of adult stem cells, which are increasingly used for research and therapeutic interventions, but extracting the cells is an arduous and often painful process. Now, researchers have found evidence that fat tissue, known as adipose tissue, may be a promising new source of valuable and easy-to-obtain regenerative cells called hematopoietic stem and progenitor cells (HSPCs), according to astudy prepublished online in Blood, the official journal of the American Society of Hematology.

28 Jan 2010

Study shows congenital HGH deficiency has no effect on normal lifespan

People profoundly deficient in human growth hormone (HGH) due to a genetic mutation appear to live just as long as people who make normal amounts of the hormone, a new study shows. The findings suggest that HGH may not be the "fountain of youth" that some researchers have suggested.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

Novo Nordisk on FORTUNE's "100 Best Companies to Work For" list for second consecutive year

Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's list of "100 Best Companies to Work For" 2010. This is the second consecutive year that Novo Nordisk has been recognized with this prestigious award. Novo Nordisk moved up to 25 from 57 in the overall list and is only one of two pharmaceutical/biotechnology companies so honored.

From Novo Nordisk 22 Jan 2010

PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

PROLOR Biotech, Inc., today announced that final data from a randomized, dose-escalating Phase I clinical study of its longer-acting version of human growth hormone (hGH-CTP) will be featured in an oral presentation by PROLOR management at the 12th Annual BIO CEO & Investor Conference to be held at the Waldorf-Astoria Hotel in New York City on February 8-9, 2010.

20 Jan 2010

Access Pharmaceuticals provides update on its Cobalamin insulin development program

ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.

20 Jan 2010

AACE sends petition to Congress opposing new Medicare policy

The American Association of Clinical Endocrinologists (AACE) sent a petition to Congress today signed by 1,325 AACE members, non-AACE member physicians, allied health professionals and patients opposing a new Medicare policy which would eliminate consultation codes for specialists.

13 Jan 2010

Growth hormone deficiency can lead to memory deficits later in life

Scientists have shown that early growth hormone supplementation in rats with growth hormone deficiency can prevent defects in memory developing later in adulthood. The study, published in the Journal of Endocrinology is the first to show that memory defects in adults as a result of growth hormone deficiency arising in childhood can be prevented by growth hormone treatment during adolescence.

13 Jan 2010

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

A new analysis found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis, published online as a Web First article today in Health Affairs and performed by researchers at The Lewin Group.

13 Jan 2010

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Emisphere Technologies, Inc. today announced that Novo Nordisk has initiated its first Phase I clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a $2 million payment to Emisphere, whose proprietary Eligen® Technology is used in the formulation of NN9924.

13 Jan 2010

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks.

30 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Growth Hormone News and Research

Further Reading

Steroids and weight loss products can accelerate hair loss, says hair loss expert

Access Pharmaceuticals initiates Cobalamin technology program for targeted delivery of siRNA therapies

Akela announces the outcomes of two legal cases involving former employees

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

PROLOR Biotech reports the EC approval of Merck's ELONVA

Adipose tissue, a promising new source of HSPCs

Study shows congenital HGH deficiency has no effect on normal lifespan

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk on FORTUNE's "100 Best Companies to Work For" list for second consecutive year

PROLOR Biotech's hGH-CTP Phase I study data to be presented at the BIO CEO & Investor Conference

Access Pharmaceuticals provides update on its Cobalamin insulin development program

AACE sends petition to Congress opposing new Medicare policy

Growth hormone deficiency can lead to memory deficits later in life

New analysis finds cost of diabetes and pre-diabetes reached $218 billion in 2007

Emisphere Technologies: Novo Nordisk initiates first Phase I clinical trial of GLP-1

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Novo Nordisk initiates share repurchase programme

Senator Arlen Specter proposes new amendment to current healthcare reform bill

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News